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Background: Colonic microbiome is thought to be involved in auto-immune multiple
sclerosis (MS). Interactions between diet and the colonic microbiome in MS are unknown.
Methods: We compared the composition of the colonic microbiota quantitatively in 25
MS patients and 14 healthy controls.Fluorescence in situ hybridization (FISH) with 162
ribosomal RNA derived bacterial FISH probes was used. Ten of the MS patients received
a ketogenic diet for 6 months. Changes in concentrations of 35 numerically substantial
bacterial groups were monitored at baseline and at 2, 12, and 23/24 weeks.
Results: No MS typical microbiome pattern was apparent.The total concentrations
and diversity of substantial bacterial groups were reduced in MS patients (P < 0.001).
Bacterial groups detected with EREC (mainly Roseburia), Bac303 (Bacteroides), and
Fprau (Faecalibacterium prausnitzii) probes were diminished the most. The individual
changes were multidirectional and inconsistent. The effects of a ketogenic diet were
biphasic. In the short term, bacterial concentrations and diversity were further reduced.
They started to recover at week 12 and exceeded significantly the baseline values after
23–24 weeks on the ketogenic diet.
Conclusions: Colonic biofermentative function is markedly impaired in MS patients.The
ketogenic diet normalized concentrations of the colonic microbiome after 6 months.
Keywords: FISH, colonic microbiota, multiple sclerosis, biofermentation, ketogenic diet
INTRODUCTION
There is a growing awareness of the significance of the human microbiome in health and
disease. Microbial colonization of the skin and epithelial surfaces protects from pathogens. The
biofermentation in the colon delivers energy from digestive leftovers and synthesizes a broad
spectrum of vitamins and hormone-like substances, which regulate metabolism and neuronal
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activity (Galland, 2014). The enormous variety of the healthy
microbiome conveys antigenic diversity to the host shaping its
immunity and autoimmunity (Berer and Krishnamoorthy, 2014).
An ever growing number of studies demonstrates the
involvement of the colonic microbiome in obesity, digestive,
endocrine, inflammatory, and auto-immune disorders including
multiple sclerosis (MS) (Berer and Krishnamoorthy, 2014;
Galland, 2014; Glenn and Mowry, 2016).
Topics, methods and results of these studies are well presented
and should not be repeated here. However, the previous studies
of the colonic microbiome in MS were restricted to identification
of microbial patterns associated with disease (Miyake et al., 2015;
Jangi et al., 2016; Tremlett et al., 2016). We found no literature
on the quantitative evaluation of the colonic microbiome in MS
patients. Microbial concentrations, however, are an important
feature, which directly measures their functional contribution
to colonic fermentation. The aim of this study was to compare
the concentrations of different microbial groups in MS patients
and healthy controls and to follow up changes in the colonic
microbiome taking place during ketogenic diet.
The option of ketogenic diet was important for the following
reasons: as long as complex microbiomes cannot be reliably
transferred, maintained and tested in vitro, all data raised
in vivo must remain observational. Therefore, interventions
simultaneously affecting the microbiome and disease are
necessary to unravel possible causality.
Ketogenic diet influences brain function, inflammation,
immunity and the colonic microbiome. It is increasingly applied
in clinical studies (Piccio et al., 2008; Kim et al., 2012; Choi et al.,
2016). Different to fasting or mono-diets, ketogenic diet can be
maintained over months and is well tolerated. Diet prescriptions
are often circumvented in real life. The compliance of the
ketogenic diet can be reliably verified through measurement of
ketone bodies in blood and urine and cannot be falsified.
MATERIALS AND METHODS
Patients/Samples
Fourteen healthy volunteers from the Laboratories of Centre for
Infectious Diseases, Faculty of Veterinary Medicine, University
of Leipzig and 25 patients with relapsing-remitting multiple
sclerosis cared for at the Charité hospital were investigated for
the composition of their colonic microbiome using fluorescence
in situ hybridization ribosomal RNA based FISH probes available
in public resources (Loy et al., 2016).
The study was reviewed and approved by institutional review
board: Ethikkomission Ethikausschuss 1 an Campus Charite
Mitte EA1/130/07.
After the baseline investigation, MS patients received a
ketogenic diet for 6 months. The ketogenic diet was designed (1)
to achieve a modest ketosis (≥500µmol/L ß-hydroxybutyrate)
in the blood, self-measured after dinner twice a week (FreeStyle
Precision, Abbott Diabetes Care Ltd.), (2) to achieve a modest
ketosis (≥500µmol/L acetoacetate) in the urine, self-measured
after dinner once a week (Ketostix, Bayer Consumer Care AG),
and (3) to maintain compliance. Patients received a booklet with
meal suggestions over 28 balanced days and were encouraged to
ingest fat. An average daily intake of<50 g carbohydrates,>160 g
fat, and <100 g protein was recommended. Patients received
detailed information about nutritional facts, glycemic load and
learned how to handle carbohydrates by an experienced
nutritional coach during group based workshops on 3
weekends.
Ten of the MS patients who were recruited for the ketogenic
diet were randomly selected for accompanying microbiome
investigations. Stools samples were collected at baseline, week
2, 12, and after 6 months (week 23–25). The evaluation of the
clinical effects on MS was not performed because of the low
number of patients.
None of the enclosed probands received antibiotics or
probiotics in the last 6 month preceding the study.
Fish
Colonic microbiota were investigated using FISH with ribosomal
RNA derived probes. Hybridizations were performed on sections
of Carnoy fixated, paraffin embedded and otherwise not
manipulated stool cylinders (Swidsinski et al., 2010). Four
micrometers thick sections were placed on SuperFrost plus slides.
A Nikon e600 fluorescence microscope was used. The images
were photo-documented with a Nikon DXM 1200F color camera
and software (Nikon, Tokyo, Japan).
Bacterial concentrations of homogeneous populations were
enumerated visually in one of the 10 × 10 fields of the ocular
raster corresponding to 10 × 10µm of the section surface
at magnification of 1,000. This number was assigned to a
concentration of× 109 bacteria/ml, which wasmost equivalent to
the calculation formula, that we had used previously (Swidsinski
et al., 2010).
In case of uneven distribution of bacteria over the microscopic
field, the positive signals were enumerated in 10 fields of the
ocular raster along the gradient of distribution and divided by 10.
Bacteria were quantified using group specific C3 probes. The
FITC marked universal probe was used in each hybridization
to evaluate the number of all bacteria, C5 marked probes with
a different specificity to C3 probes were used to determine
the spatial relation of different bacterial groups to each
other.
Only signals that hybridized with a specific FISH probe and
the universal FISH probe, but did not hybridize with specific
FISH probes from unrelated bacterial groups, were enumerated
(Swidsinski, 2006).
FISH Probes
One hundred sixty-two bacterial FISH probes available from
public resources were applied for the comparative analysis of
the colonic microbiome in healthy controls and MS patients
(Tables 1A,B). The names of the FISH probes are listed according
to abbreviations of the probeBase resource (http://probebase.csb.
univie.ac.at/node/8) (Loy et al., 2016) and the details to FISH
probe specificity and hybridization conditions are given. The
Fprau probe is described in reference (Suau et al., 2001).
Probes in Table 1 are alphabetically ordered to subgroups
according to abundancy and specificity as described in the result
section.
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TABLE 1 | Applied FISH-probes.
Part A
Substantial groups
Essential (N = 3)
Erec482 (Eubacterium rectale, Clostridium coccoides group)
Bac303 (most Bacteroidaceae)
Fprau (Faecalibacterium prausnitzii)
Individual pioneer (N = 4)
Bif153 Genus Bifidobacterium
Cdif198 Clostridium difficile
Clit135 Clostridium lituseburense group including C. difficile
Ebac1790 Enterobacteriaceae
Individual substantial (N = 28)
ACI623 Acidaminococcaceae sp. (not the Selenomonas species)
AKK406 Akkermansia
Ato291 Atopobium cluster
Bbif186 B. bifidum
Blon1004 B. longum
Bputre698 Bacteroides putredinis
Burkho Burkholderia spp.
Ceut705 C. eutactus, Coprococcus sp.
Chis150 Clostridium histolyticum
Cor653 Coriobacterium group
Cvir1414 Clostridium viride group
Ecyl387 Eubacterium cylindroides
Ehal1469 Eubacterium hallii
Eram997 Eubacterium ramulus
Lab158 Lactobacillus sp., Enterococcus sp.
Muc1437 Akkermansia muciniphila
Myc657 Mycobacterium subdivision (mycolic acid-containing actinomycetes)
Phasco741 Phascolarctobacterium faecium
Pnig657 Prevotella nigrescens
ProCo1264 Ruminococcus productus
Rbro730 Clostridium sporosphaeroides, Ruminococcus bromii, Clostridium
leptum
Rfla729 Ruminococcus albus
SFB1 Segmented filamentous bacteria
SNA Sphaerotilus natans
Strc493 most Streptococcus spp.
SUBU1237 Burkholderia spp., Sutterella spp.
Urobe63a Ruminococcus obeum-like
Veil 223 Veillonella
Ver620 Verrucomicrobium
Part B
Includes probes with extremely low occurrence and concentrations and
probes with uncharacteristic signals:
Accidental groups (N = 88)
To low in occurrence and concentrations for statistical analysis
MIB661 mouse intestinal bacteria
AER66 Aeromonas spp.
Alac1438 Anaerococcus lactolyticus
ARC1430 Arcobacter
Avag1280 Anaerococcus vaginalis
Bbrel198 B. breve
(Continued)
TABLE 1 | Continued
Bden82 B. dentium
BFV530 Bacteroides forsythus
Bif1278 Bifidobacterium spp.
Burcep Burkholderia cepacia
CAP365 Capnoytophaga sp.
Capno Capnocytophaga sputigena
Cj490 Campylobacter jejuni
CLOBU1022 Clostridium butyricum,
Cperf 191 Clostridium perfringens
Cra757 Clostridium ramosum assemblage
Csac67 Clostridium saccharogumia
CST440 Group 1 clones closely related to Clostridium stercorarium
DSV1292 some Desulfovibrio and Bilophila wadsworthia
DSV687 most Desulfovibrionales
E.bar1237 Eubacterium barkeri
E.bif462 Eubacterium biforme
E.con1122 Eubacterium contortum
E.cyl461 Eubacterium cylindroides
E.cyl466 Eubacterium cylindroides
E.dol183 Eubacterium dolichum
E.had579 Eubacterium hadrum
E.len194 Eubacterium lentum
E.lim1433 Eubacterium limosum
E.mon84 Eubacterium moniliforme
E.mul Eubacterium multiforme
E.sab Eubacterium saburreum
E.ven66 Eubacterium ventriosum
Enfl84 Enterococcus faecalis
Enfm 93 Enterococcus faecium
Fnec996 Fusobacterium necrophorum
Fnuc133 Fusobacterium nucleatum
GAN1237 Helicobacter ganmani
Haeinf Haemophilus influenzae
HEP642 Helicobacter hepaticus
Hpy-1 Helicobacter pylori
Hyo1210 Brachyspira hyodysenteriae
Lbuc668 Leptotrichia buccalis
Lis1255 Genera Listeria, Brochothrix
Lis637 Genus Listeria,
Lpara Lactobacillus casei
Lzeae Lactobacillus zeae
Pae997 Pseudomonas spp.
Pamic1435 Parvimonas micra
Pana134 Peptostreptococcus anaerobius
Pden654 Prevotella denticola
Pilosi1405 Brachyspira pilosicoli
Pilosi209 Brachyspira pilosicoli
Pint649 Prevotella intermedia
Pint657 Prevotella intermedia
Pnasa1254 Peptoniphilus asaccharolyticus
Pnhar1466 Peptoniphilus harei
Pnivo731 Peptoniphilus ivorii
POGI Porphyromonas gingivalis
(Continued)
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TABLE 1 | Continued
Ppu Pseudomonas spp.
Ppu56a Pseudomonas putida
Ppu646 Pseudomonas spp.
PRIN Prevotella intermedia
Saga Streptococcus agalactiae
SAL3 Genus Salmonella
Sau Staphylococcus aureus
Saur327 Staphylococcus
Saur72 Staphylococcus aureus
Ser1410 Genus Brachyspira
SGD229 Genus Desulfotomaculum
Sita649 Candidatus Sphaeronema italicum
Spn Streptococcus pneumoniae
Spy Streptococcus pyogenes
Staaur Staphylococcus aureus
Staph747 Staphylococcus spp.
STEBA1426 Sterolibacterium lineage
Stemal Stenotrophomonas maltophilia
Strpyo (Streppyo) Streptococcus pyogenes
Sval428 Some Desulfobulbaceae
TM7305 subdivision 1 of candidate division TM7
Trep-D3-4 32 PT1 Treponema refringens
Trep-D4-4 32 PT3 clone DDKL-20 Treponema refringens
Trep-HW 170 PT6 clone DDKL-4 Treponema phagedenis
Trep-T5-4 32 PT2 Treponema refringens
Urobe63b Ruminococcus obeum-like
VEPA Veillonella parvula
VIB572a Genus Vibrio
Y Yersinia
FISH probes with signals which could not be definitively assigned to a
specific group of bacteria (N = 31)
Alf 1b (Alpha) Alphaproteobacteria, some Deltaproteobacteria, Spirochaetes
Arch 915 Archaea
B for Bacteroides forsythus
B(T)AFO Tannerella forsythensis
Bact for Bacteroides forsythus
Bang198 B. angulatum
Bfra602 most Flavobacteria, some Bacteroidetes
Bmy843 Bacillus
BORR4 Genus Borrelia
Bvulg1017 Bacteroides vulgatus
CF319a most Flavobacteria, some Bacteroidetes
CFB560 subgroup of Bacteroidetes, CFB division
Clept1240 Clostridium leptum
Efaec Enterococcus faecalis, Enterococcus sulfuricus
Enc131 Enterococcus spp and other
Ent Enterobacteriaceae except Proteus spp.
FUS664 most Fusobacterium sp
FUSO Fusobacterium sp.
MIB724 mouse intestinal bacteria
PBR2 Bifidobacterium breve
PseaerA Pseudomonas aeruginosa
PseaerB Pseudomonas aeruginosa
(Continued)
TABLE 1 | Continued
Rint623 Roseburia cecicola, Roseburia intestinalis
Rrec584 Roseburia genus
SRB385Db Desulfobacterales
ssp F suc Fibrobacter succinogenes subsp. Succinogenes
STA Staphylococcus spp.
Str(STR2) Streptococcus spp
TRE308 Treponema sp.
TrepGen 725 S-S-Trep Genus725 (202)
TW652 Tropheryma whippelii
FISH probes which delivered identical results to other probes (N = 8)
EC1531 E. coli
ECO1167 (ECO 45A) Escherichia coli
ENT183 Enterobacteriaceae
GAM42a Gamma-proteobacteria
HGC69a Actinobacteria (high G+C Gram-positive bacteria)
Bif164 Bifidobacteriaceae, Bifidobacterium spp.
EubII Phylum Planctomycetes
EubIII Phylum Verrucomicrobia
We performed hybridizations with all probes but excluded
from analysis 31 of these probes, because they showed multiple
uncharacteristic signals, in form and distribution not resembling
bacteria or cross-reacting with non-related bacterial groups and
eight FISH probes that were identical to related probes for the
same species.
To reduce the number of unnecessary investigations, while
following the impact of the ketogenic diet on the colonic
microbiome, only 35 bacterial groups which were found to
have substantial occurrence (in at least 20% of individuals) and
concentrations (>109 in at least one of the stool samples of one
individual) were applied.
Statistical Analysis
Differences between groups were evaluated using the two sided
t-StudentU-test. Data are presented as means± SD, P <0.05 was
considered statistically significant.
RESULTS
Eligibility of the FISH Probes for Analysis of
the Stool Microbiome
Three bacteria detected with EREC (mainly Roseburia), Bac303
(Bacteroides), and Fprau (Faecalibacterium prausnitzii) probes
were always present in healthy human controls and MS patients
and contributed to about half of the colonic microbiome in each
subject. We called these groups essential bacteria.
All other investigated bacterial groups were individual,
detectable only in a subset of patients. We called them individual
bacterial groups.
Twenty-eight of the individual bacterial groups were found in
at least 30% of the probands (mostly 50–70%) in concentrations
of higher than 109 bacteria/ml. They contributed substantially
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to the colonic microbial mass. We called them individual
substantial groups.
Four of the individual bacterial groups including Bif
(Bifidobacteriacae), Ebac (Enterobacteriaceae), Clit (Clostridium
lituseburense), and Cdif (Clostridium difficile) are often
found prevalent in newborns, after antibiotic treatment
and convalescence patients and thus represent bacterial groups
with pioneer function. We evaluated these groups separately.
Individual bacterial groups detected with 88 FISH probes
(Table 1B) were observed in one, maximal two individuals
in marginal concentrations of ≤0.1 ×109ml. We called these
individual marginal bacterial groups. Because of the uneven
distribution of such bacteria over the stool cylinder, their
quantification was highly unreliable.
Thirty-one of investigated FISH probes showed multiple
uncharacteristic signals, in form and distribution, cross-reacting
with unrelated bacterial groups. The appearance of these signals
was not visually different in MS and healthy controls. Because of
the uncertainty of what exactly is measured, we did not perform
the quantitative analysis of the results detected with these probes.
Eight FISH probes, showed identical results with related
probes for the same species/bacterial group, were also not
quantitatively evaluated.
Microbiome in Healthy Controls and MS
Patients Prior to Diet Intervention
The morphologic appearance of single bacteria detected with
corresponding FISH probes was the same in MS patients and
healthy controls. The distribution of bacteria over the stool
cylinder surface was not noticeably different. None of the
investigated bacterial groups, including groups with unspecific
signals, demonstrated prevalence or absence in MS patients,
which could be interpreted in terms of Koch’s postulates.
As long as bacterial groups were compared pairwise, the
differences between MS and healthy patients were discordant,
gradual and moderate, reaching only in 9 groups statistical
significance (Table 2). The concentrations of most investigated
groups in MS were decreased. Six groups were slightly
increased and included Cor653 (Coriobacterium group),
Cvir1414 (Clostridium viride group) Ehal (Eubacterium hallii),
Ecyl387 (Eubacterium cylindroides), Lab158 (Lactobacillus sp.,
Enterococcus sp.), Rfla729 (Ruminococcus albus) bacterial groups.
Seven substantial individual bacterial groups had similar high
concentrations in MS and healthy controls.
Due to uncertain occurrence and low concentrations, which
was difficult to quantify, we did not compare the single marginal
bacterial groups in MS patients and controls quantitatively. No
rise of single marginal groups in MS patients was observed.
The difference in the microbiome of MS patients and healthy
controls became striking, when concentrations of numerically
substantial groups were summarized and considered as a whole
(Table 2, marked in bold). The diversity of all substantial groups
in MS patients was reduced by 36% (P < 0.001), the mean
sum concentrations of all substantial bacterial groups were
reduced by 24% (65 vs. 85.4 ×109/bacteria/ml., P < 0.001)
compared to healthy controls. The decrease in concentrations
was most profound in the essential bacteria group (32%) and
less impressive in individual substantial (19%) and pioneer
groups (14%).
Changes of the Colonic Microbiome with
the Ketogenic Diet in 10 MS Patients
The changes in the microbiome during the ketogenic diet
were univocal. Except for Akkermansia, all groups of bacteria
demonstrated consistently more or less marked decreases,
leading to a reduction of the total bacterial concentrations of the
substantial bacteria from 65 to 25× 109 bacteria per ml at week 2.
Some of the bacterial groups fell below detection level, resulting
in further decline of the bacterial diversity from 48 to 36%.
However these tendencies were temporary.
The total bacterial concentrations in MS patients started to
increase at week 12, reaching values typical for healthy controls
at week 23/24, being then significantly higher than bacterial
concentrations in MS patients prior to diet and statistically not
different to mean bacterial concentrations in healthy controls
(P = 0.7). This increase was consistent for all but the pioneer
bacterial groups andAkkermansia. The concentrations of pioneer
bacterial groups fell and remained low, the concentrations of
Akkermansia increased initially but then declined during the
ketogenic diet.
DISCUSSION
Previous investigation, using high throughput DNA sequencing
technologies in large scale 16S rRNA or shotgun metagenomic
sequencing, demonstrated miscellaneous changes in the
composition of the colonic microbiome, which correlated with
MS, MS-onset, -therapy or -relapse (Kim et al., 2012; Berer and
Krishnamoorthy, 2014; Galland, 2014; Miyake et al., 2015; Glenn
and Mowry, 2016; Jangi et al., 2016; Tremlett et al., 2016). Both
single bacterial groups were found differently represented and
also the whole microbiome was aberrantly composed. While
the alpha diversity of MS and the healthy microbiome was
similar, the beta diversity differed significantly. In ecology, alpha
diversity expresses the mean species diversity in sites or habitat at
a local scale, while beta diversity is the ratio between regional and
local diversity. The differences indicated shifts in composition
of the MS microbiome. The meaning of these observations is
unclear. The pure occurrence of bacteria does not automatically
mean that they are relevant or biochemically active. The vacant
niches may be occupied by chance.
Although we applied publically available FISH probes
as broadly as possible and included all groups covering
numerically substantial components of the colonic microbiome,
no conclusions to the entire biodiversity are possible, since FISH
reliably detects only bacteria in concentrations of higher than 105
per ml.
However, while sequence analysis is perfect for identification
of specific occurrence patterns, its information on physical
abundance and contribution of bacteria to biofermentation is
poor. Abundance of bacteria within the fecal mass however
directly expresses their biofermenting power.
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TABLE 2 | Colonic microbiome in healthy and MS patients prior to and during the ketogenic diet.
Week Healthy MS t-test
A B C D E
Initial 2 12 23/24
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD
concentrations concentrations concentrations concentrations concentrations
Diversity of microbiome as %
of substantial bacterial groups
(35) positive in each patient
75 ± 15 48 ± 19 35 ± 13 38 ± 6.9 51 ± 10.6 A/B,C,D,E P < 0.001; B/C P = 0.03–0.05; E/B
P = 0.07; E/C P < 0.001; E/D P = 0.05
All bacterial groups x109
bacteria/ml
85.4 ± 25.6 65 ± 23.1 25.1 ± 17.2 36.4 ± 16.8 83 ± 25.8 A/B,C,D P < 0.001; A/E P = 0.7; B/C,D
P < 0.001; E/B P = 0.02; E/C,D P < 0.0001
ESSENTIAL
All Essential bacteria (N = 3) 36.2 ± 14.7 24.6 ± 9.5 10.7 ± 8.4 16.1 ± 7.4 34.4 ± 10 A/B,C,D P < 0.001; A/E P = 0.4; B/C
P = 0.001; B/D P = 0.7; E/B P = 0.05; E/C,D
P < 0.001
Erec482 (Eubacterium rectale,
Clostridium coccoides group)
11.7 ± 6.9 6.7 ± 5.8 6.1 ± 2.8 6.4 ± 5.3 10.7 ± 7.3 A/B,C,D P = 0.02–0.002; A/E P = 0.6; B/C
P = 0.2; B/D P = 0.9; E/B,C,D P = 0.03–0.02
Bac303 (Bacteroides) 12.9 ± 5.3 9.1 ± 4.9 3.4 ± 3.1 4.2 ± 2.7 11.4 ± 6.2 A/B,C,D P<0.001–0.006; A/E P=0.3; B/C,D
P=0.001-0.002; E/B P=0.09; E/C,D P<0.001
Fprau (Faecalibacterium
prausnitzii)
11.6 ± 5.9 8.8 ± 5.1 2.7 ± 4.2 5.7 ± 4 12.2 ± 7.9 A/B P < 0.05; A/E P = 0.8; B/C,D P = 0.001;
B/D P = 0.08; E/B P = 0.05; E/C,D
P < 0.001–0.007
INDIVIDUAL PIONEER
All Individual pioneer bacteria
(N = 4)
7.8 ± 5 6.7 ± 5.3 2.5 ± 3.2 1.9 ± 3 2.7 ± 4.3 A/B P = 0.4: A/C,D P = 0.001–0.005; A/E
P = 0.004; B/C P = 0.03; B/D P = 0.008; E/B
P = 0.03; E/C,D P=0.5-0.2
Ebac1790
(Enterobacteriaceae)
0.25 ± 0.8 0.5 ± 1.4 0.4 ± 1.2 0.05 ± 0.2 0.15 ± 0.8 All P > 0.25
Bif153 (Genus Bifidobacterium) 7.1 ± 5.5 5.7 ± 4.9 2.1 ± 2..4 1.8 ± 3 2.1 ± 3 A/B P = 0.3; E/C,D P > 0.85; A/C,D
P < 0.001; B/C,D P = 0.02–0.03; B/E
P = 0.008; E/A P < 0.001
Clit135 (Clostridium
lituseburense group including
C. difficile)
0.5 ± 0.86 0.4 ± 1.2 0 0.03 ± 0.09 0.2 ± 0.6 All P > 0.1
Cdif198 (Clostridium difficile) 0.04 ± 0.09 0.04 ± 0.2 0 0.001 ± 0.003 0.2 ± 0.6 All P > 0.3
INDIVIDUAL SUBSTANTIAL
All Individual substantial
bacteria (N = 28)
41.7 ± 17.3 33.8 ± 16.8 11.8 ± 9 18.3 ± 11.6 46.9 ± 18.9 A/B P = 0.08; A/C,D P < 0.001; A/E
P = 0×.3: B/C P < 0.001; B/D P = 0.006;
E/B P = 0.02; E/C,D P < 0.001
ACI623 (Acidaminococcaceae
sp. not the Selenomonas
species)
1.4 ± 1.9 0.6 ± 1.4 0.4 ± 1.3 0.2 ± 0.4 0.5 ± 0.7 A/B, P = 0.0.1; A/C P = 0.2; A/D P = 0.08;
A/E P = 0.01; B/C P = 0.8; B/D P = 0.4; E/B
P = 0.7; E/C,D P = 0.5–0.7
AKK406 (Akkermansia) 2.3 ± 3.7 1.1 ± 2.7 2.1 ± 3.8 0.7 ± 2.2 1 ± 1.7 A/B P = 0.2; A/C P = 0.7; A/D P = 0.3; A/E
P = 0.2; B/C P = 0.2; B/D P = 0.9; E/B
P = 0.7; E/C,D P = 0.4–0.9
Ato291 (Atopobium cluster) 3.8 ± 2.9 2.9 ± 3.1 0.45 ± 0.5 2.6 ± 2.3 4.1 ± 3.1 A/B P = 0.3; A/E P = 0.7; B/C P = 0.02; E/B
P = 0.2
Bbif186 (B. bifidum) 0.3 ± 0.9 0.1 ± 0.4 0 0 0.05 ± 0.2 A/B P = 0.3; A/E P = 0.2; B/E P = 0.6
Blon1004 (B. longum) 0.7 ± 1.2 0.3 ± 0.8 0.2 ± 0.4 0 0.5 ± 0.9 A/B P = 0.3; A/E P = 0.7; B/C P = 0.7; E/B
P = 0.5
Bputre698 (Bacteroides
putredinis)
0.8 ± 1.6 0.06 ± 0.2 0.05 ± 0.2 0 0.3 ± 0.8 A/B P = 0.03; A/E P = 0.2; B/C P = 0.9; E/B
P = 0.2; E/C P = 0.4
Burkho (Burkholderia spp.) 0.7 ± 0.7 0.7 ± 1.2 0.8 ± 0.7 0.001 ± 0.03 0.9 ± 1.5 A/B P = 0.98; B/C P = 0.5; E/B P = 0.7; E/C
P = 0.4
Ceut705 (C. eutactus,
Coprococcus sp.)
3.0 ± 4.4 1.7 ± 2.9 0.15 ± 0.3 0.2 ± 0.4 1 ± 2 A/B P = 0.2; A/C P = 0.05; A/E P = 0.07; B/C
P = 0.1; E/B P = 0.4; E/C,D P = 0.2
(Continued)
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TABLE 2 | Continued
Week Healthy MS t-test
A B C D E
Initial 2 12 23/24
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD
concentrations concentrations concentrations concentrations concentrations
Chis150 (Clostridium
histolyticum)
0.6 ± 1.2 0.05 ± 0.2 0.03 ± 0.1 0.04 ± 0.1 1 ± 2.3 A/B P = 0.03; A/E P = 0.5; B/C,D
P = 0.8–0.9; E/B P = 0.08
Cor653 (Coriobacterium group) 0.5 ± 0.8 0.8 ± 1.2 0.5 ± 1.1 0.1 ± 0.3 0.09 ± 0.2 A/B P = 0.0.3; A/C, P = 0.9; A/E P = 0.04;
B/C P = 0.5; E/B P = 0.02; E/C,D P = 0.1
Cvir1414 (Clostridium viride
group)
1.9 ± 2.1 2.2 ± 2.7 0.5 ± 0.4 2 ± 2.6 4.7 ± 3.6 A/B P = 0.7; A/C P = 0.04; A/E P = 0.002;
B/C P = 0.05; E/B,C,D <0.01
Ecyl387 (Eubacterium
cylindroides)
0.7 ± 0.5 1 ± 1.2 0.3 ± 0.7 0.3 ± 0.6 0.3 ± 0.8 A/B P = 0.0.1; A/E P = 0.1; B/C P = 0.1; E/B
P = 0.05
Ehal1469 (Eubacterium hallii) 0.6 ± 0.9 1.4 ± 1.9 1.2 ± 1.2 1.7 ± 2.1 2.9 ± 2.1 A/B P = 0.04; A/E P < 0.001; B/C P = 0.7;
E/B,C P < 0.01
Eram997 (Eubacterium
ramulus)
0.3 ± 1.3 0.09 ± 0.2 0 0 0.2 ± 0.8 A/B P = 0.0.4; A/E P = 0.8; B/C P = 0.2; E/B
P = 0.5
Lab158 (Lactobacillus sp.,
Enterococcus sp.)
0.1 ± 0.2 1.2 ± 2.9 0.1 ± 0.3 0.02 ± 0.02 0.1 ± 0.4 A/B P = 0.05; A/E P = 0.7; B/C P = 0.3;
E/C,D P = 0.1
Muc1437 (Akkermansia
muciniphila)
2.8 ± 3.9 1.7 ± 3.4 1.8 ± 4 0.5 ± 1.5 1 ± 1.2 A/B P = 0.3; A/E P = 0.1; B/C P = 0.9; E/B
P = 0.5
Myc657 (Mycobacterium
subdivision, mycolic
acid-containing
Actinomycetes)
3.1 ± 1.5 3 ± 3.1 1.2 ± 1.6 3.3 ± 3 4.2 ± 3.8 A/B P = 0.9; A/E P = 0.2; B/C P = 0.09; E/B
P = 0.3
Phasco741
(Phascolarctobacterium
faecium)
0.6 ± 0.9 0.6 ± 2.1 0 0.4 ± 0.8 0.4 ± 0.7 A/B P = 0.9; A/E P = 0.7; B/C P = 0.4; E/B
P = 0.7
Pnig657 (Prevotella nigrescens) 2.2 ± 3.7 0.2 ± 0.6 0 0 1.1 ± 3 A/B P = 0.01; A/E P = 0.4; B/C P = 0.3; E/B
P = 0.3
ProCo1264 (Ruminococcus
productus)
0.7 ± 2 0.02 ± 0.08 0 0.09 ± 0.3 0.8 ± 1.8 A/B P = 0.08; A/E P = 0.7; B/C P = 0.5; E/B
P = 0.03
Rfla729 (Ruminococcus albus) 2.2 ± 3.2 5.1 ± 3.2 1.4 ± 2.3 0.6 ± 1.3 6.5 ± 4.4 A/B P = 0.002; A/E P < 0.001; B/C P = 0.02;
E/B P = 0.2
SFB1 (Segmented filamentous
bacteria)
2.3 ± 3.3 1.5 ± 3.8 0.4 ± 0.8 1.9 ± 3.5 3.7 ± 4.1 A/B P = 0.4; A/E P = 0.2; B/C P = 0.4; E/B
P = 0.1
SNA (Sphaerotilus natans) 4.3 ± 3.7 3.2 ± 3.7 0.3 ± 0.4 0.001 ± 0.003 5.7 ± 4.8 A/B P = 0.3; A/E P = 0.2; B/C P = 0.02; E/B
P = 0.05
Strc493 (most Streptococcus
spp.)
1.3 ± 3.3 0.8 ± 1.5 0.01 ± 0.03 0.4 ± 1.2 1 ± 1.7 A/B P = 0.4; A/E P = 0.8; B/C P = 0.1; E/B
P = 0.6
SUBU1237 (Burkholderia spp.,
Sutterella spp.)
1.7 ± 2.6 0.6 ± 1.2 0.1 ± 0.3 0.1 ± 0.3 1.4 ± 1.6 A/B P = 0.08; A/E P = 0.7; B/C P = 0.2; E/B
P = 0.1
Urobe63a (Ruminococcus
obeum-like)
1.6 ± 2.3 1.6 ± 2.8 0.06 ± 0.2 0.7 ± 1.8 2.1 ± 1.9 A/B P = 0.9; A/E P = 0.5; B/C P = 0.1; E/B
P = 0.5
Veil223 (Veillonella) 0.1 ± 0.3 0.04 ± 0.2 0 0.2 ± 0.4 0.16 ± 0.3 A/B P = 0.2; A/E P = 0.8; B/C P = 0.5; E/B
P = 0.2
Ver620 (Verrucomicrobium) 1.7 ± 3.9 1 ± 2.7 0 1.9 ± 3.6 1.2 ± 2.4 A/B P = 0.5; A/E P = 0.6; B/C P = 0.2; E/B
P = 0.9
Our data quantifying microbial participants clearly
demonstrate the impaired colonic function in patients with
MS. Both concentrations and biodiversity of numerically
substantial bacterial groups were markedly reduced in MS.
Essential bacteria were most, individual substantial bacteria less
depleted, while pioneer bacteria were nearly unchanged.
This grading of suppression matches well with the proposed
role of these groups for colonic function. Essential bacteria
are present in every healthy person in large concentrations,
contributing roughly to approximately half of the mass
of the colonic microbiome. They are obviously important
for colonic fermentation and represent main fermentative
groups in human. The individual substantial bacterial
groups are present only in subsets of healthy persons in
varying concentrations, which are each distinctly lower than
those of the essential bacterial groups. Their presence is
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dispensable for colonic fermentation. However, their diversity
is high, composition specific for each subject, indicating
that they fulfill special tasks not covered by the essential
bacterial groups. Despite markedly lower concentrations,
when compared to essential bacterial groups, the individual
substantial groups constitute together another half of the colonic
biomass.
Pioneer bacteria are usually found in low concentration in
healthy adults. Their concentrations are high in newborns after
antibiotic treatment and in convalescence, while the colonic
microbiome is reshaped (Swidsinski et al., 2016).
The fall in concentration in MS patients was gradual,
decreasing from essential to individual substantial and further
to pioneer bacterial groups. This suggests that the suppression is
not due to the loss of responsible microbial groups or reshaping
of the microbiome. It presumably results from the general
downregulation of the colonic biofermentative function and
affects mainly biofermentative active groups, leaving bacterial
groups with other specific tasks untouched.
We observed no changes in the microbiome that could be
specific for MS.
While mean concentrations of all essential bacteria detected
with EREC (mainly Roseburia), Bac303 (Bacteroides), Fprau
(F. prausnitzii) probes were consistently reduced inMS, the shifts
in individual substantial bacterial groups were multidirectional
with concentrations of some bacterial groups unchanged,
increased or reduced when compared to healthy controls.
Although some of the differences reached the level of statistical
significance, the fluctuations in concentrations of individual
substantial bacterial groups were moderate and in the range
of those, when unmatched groups of subjects are compared
with each other. Similar fluctuations are documented while
describing microbiome composition in other pathologies such
as diarrhea, irritable bowel syndrome, inflammatory bowel
disease, and others (Mai et al., 2016; Swidsinski et al.,
2016).
Since the microbiome is influenced by a multiplicity of
racial, occupational, social, regional, and geographic factors,
matching for all of them would be an impossible task.
Mean values raised in small cohorts should therefore be
critically evaluated, even when they occasionally prove to be
statistically highly significant (Mai et al., 2016). Our data
allow definitively no conclusions to whether the observed
alterations in concentrations of colonic bacteria precede, result,
specifically accompany MS or rely on independent coincident
processes such as aberrant immunity, impaired digestion or
simply changed behavior. However, they clearly demonstrate
that the perturbation of the microbiome in MS is not inherent
and inevitable but can be definitively corrected with diet,
supplementation and other means as assumed previously (Tanca
et al., 2015).
After 6 months on the ketogenic diet, the sum concentrations
of the substantial microbial groups in MS patients increased
significantly when compared to the period prior to intervention
(83 vs. 65 × 109 bacteria/ml; P = 0.02) and became
indistinguishable from the healthy group (83 vs. 85.4 × 109
bacteria/ml. P = 0.7).
Our data also demonstrate that the tracking of the changes in
the microbiome should not be restricted to a single time point,
but needs surveillance over longer periods of time.
The reduction of microbial concentrations observed 2 weeks
after the start of the diet was dramatic, the ranges of
suppression were comparable to antibiotics effects (Swidsinski
et al., 2016). Concentrations of some individual substantial
groups fell under detection limit, leading to further drop in the
microbial diversity from mean 48 to 35 percent. However, the
processes behind dietetic and antibiotic effects are principally
different.
The improvement with antibiotic treatment occurred only
after the end of treatment, while with the ketogenic diet, the
improvement occurred in succession of the diet and the long-
term effects of diet were opposite to the immediate response to
the intervention. Although the diversity of the microbiome did
not reach the values typical for the healthy population, at the
end of the observation period, after 6 months on the ketogenic
diet, it completely recovered as compared to basic values prior to
treatment.
Obviously the increase in microbial concentrations was
mainly due to improvement of colonic function and achieved
by preexisting microbial groups. Typical for convalescence after
depletion of the colonic microbiome following antibiotic use,
stroke or inflammation is a temporary excess of pioneer bacterial
groups. Such excess was not observed with the ketogenic diet. In
contrast, the pioneer bacterial groups remained reduced over the
whole duration of the ketogenic diet (p < 0.05–0.008), indicating
an absence of substantial microbiome reshaping.
Although the concentrations and the biodiversity of colonic
microbiota are strong markers of the intensity of the microbial
metabolism, the shifts in bacterial groups per se do not reveal
the exact metabolic changes taking place. The role of single
substances and metabolites in neurologic disorders is still to be
unraveled and follow our preliminary observations.
Summarizing, we state that colonic microbiome and
neuropathology are closely interrelated. Concentrations
of numerically substantial biofermentative bacteria are
significantly reduced in MS patients. The microbial shifts
can be reliably quantified and monitored by FISH under
ambulatory conditions. The ketogenic diet for 6 months
completely restored the microbial biofermentation mass and
is an interesting interventional tool for prospective clinical
studies.
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